GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Shiller PE Ratio

Helix BioPharma (TSX:HBP) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Helix BioPharma Shiller PE Ratio Historical Data

The historical data trend for Helix BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Shiller PE Ratio Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Helix BioPharma's Shiller PE Ratio

For the Biotechnology subindustry, Helix BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Shiller PE Ratio falls into.


;
;

Helix BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Helix BioPharma's E10 for the quarter that ended in Jan. 2025 is calculated as:

For example, Helix BioPharma's adjusted earnings per share data for the three months ended in Jan. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-0.15/127.4427*127.4427
=-0.150

Current CPI (Jan. 2025) = 127.4427.

Helix BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201504 -0.150 99.710 -0.192
201507 -0.100 100.579 -0.127
201510 -0.150 100.500 -0.190
201601 -0.150 100.184 -0.191
201604 -0.100 101.370 -0.126
201607 -0.150 101.844 -0.188
201610 -0.200 102.002 -0.250
201701 -0.150 102.318 -0.187
201704 -0.150 103.029 -0.186
201707 -0.050 103.029 -0.062
201710 -0.100 103.424 -0.123
201801 -0.150 104.056 -0.184
201804 -0.100 105.320 -0.121
201807 -0.100 106.110 -0.120
201810 -0.050 105.952 -0.060
201901 -0.100 105.557 -0.121
201904 -0.100 107.453 -0.119
201907 -0.100 108.243 -0.118
201910 -0.100 107.927 -0.118
202001 -0.100 108.085 -0.118
202004 -0.100 107.216 -0.119
202007 -0.100 108.401 -0.118
202010 -0.200 108.638 -0.235
202101 -0.100 109.192 -0.117
202104 -0.100 110.851 -0.115
202107 -0.100 112.431 -0.113
202110 -0.050 113.695 -0.056
202201 -0.050 114.801 -0.056
202204 -0.050 118.357 -0.054
202207 0.000 120.964 0.000
202210 -0.050 121.517 -0.052
202301 -0.050 121.596 -0.052
202304 -0.050 123.571 -0.052
202307 -0.054 124.914 -0.055
202310 -0.150 125.310 -0.153
202401 -0.100 125.072 -0.102
202404 -0.043 126.890 -0.043
202407 -0.108 128.075 -0.107
202410 -0.150 127.838 -0.150
202501 -0.150 127.443 -0.150

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Helix BioPharma  (TSX:HBP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Helix BioPharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.